title: Treatments of vitiligo: what's new at the horizon.
abstract: Vitiligo is a manageable disease. However, current vitiligo treatments can be considered suboptimal as they do not guarantee high efficacy and cannot be standardized for most patients. Recently, combination therapies have been introduced in order to obtain better results and reduce risks in the management of the disease. Novel efficacious products are hereunder discussed to improve the therapeutic options for vitiligo patients.
authors.affiliation: University of Rome G Marconi, Rome, Italy.
authors.forename: Torello M
authors.initials: TM
authors.lastname: Lotti
authors.forename: Jana
authors.initials: J
authors.lastname: Hercogová
authors.forename: Robert A
authors.initials: RA
authors.lastname: Schwartz
authors.forename: Dionigi
authors.initials: D
authors.lastname: Tsampau
authors.forename: Igor
authors.initials: I
authors.lastname: Korobko
authors.forename: Aldona
authors.initials: A
authors.lastname: Pietrzak
authors.forename: Natasa Teovska
authors.initials: NT
authors.lastname: Mitrevska
authors.forename: Yan
authors.initials: Y
authors.lastname: Valle
authors.forename: Gionata
authors.initials: G
authors.lastname: Buggiani
mesh_terms: D003879:Dermatologic Agents / Q000627:therapeutic use*; D003880:Dermatology / Q000639:trends; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053685:Laser Therapy / Q000379:methods*; D010789:Phototherapy / Q000379:methods*; D016038:Skin Transplantation / Q000379:methods*; D016896:Treatment Outcome; D014820:Vitiligo / Q000628:therapy*
chemical_list: D003879:Dermatologic Agents; D007166:Immunosuppressive Agents